ERBB2 and cancer: In phase I clinical study of RC48 in the therapy of solid cancer, the subgroup analysis of GC demonstrated that RC48 has outstanding anti-cancer ability on HER2+ GC, and its ORR and DCR reached 21.3% and 46.8%, respectively (Xu et al., 2021).